Delcath Systems

DELCATH SYSTEMS INC

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

$BTC

CGEM

DCTH

DSGN

MSTR

NPCE

U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday.

MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

AIRE

BAOS

BREA

CREV

HOUR

LICN

LKCO

MGIH

SOBR

SPRC

SVRE

TCTM

ZCAR

Why Zoomcar Shares Are Trading Higher By Around 142%; Here Are 20 Stocks Moving Premarket

jim cramer chart shutter

Long Ideas

Media

ADMA

&#34;Mad Money&#34; host Jim Cramer said, &#34;Any time there&#39;s immunity-compromised patients, there&#39;s some big money down the road.&#34;

&#39;This Is A Very Speculative Situation,&#39; Jim Cramer On ADMA Biologics

Delcath Systems Inc

Press Releases

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

Management

Beta Bionics Announces Board Appointment of Gerard Michel

BBNX

AngioDynamics

Axogen

Beta Bionics

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

Butterfly Network, Inc. Class A Common Stock

Butterfly Network

CeriBell

ClearPoint Neuro

CVRx

Electromed

iRadimed

Pulmonx

NeuroPace

Nevro

Orthofix Medical

Outset Medical

Senseonics Holdings

SI-BONE

Semler Scientific

SANUWAVE Health

Surmodics

Neuronetics

Tactile Systems Technology, Inc. - Common Stock

Tactile Systems Tech

Treace Medical Concepts, Inc. - Common Stock

Treace Medical Concepts

Varex Imaging

ZimVie

HC Wainwright & Co.

Craig-Hallum

Canaccord Genuity

Stephens & Co.

Comments

Delcath Systems

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga